Lannett Company, Inc. (NYSE: LCI), a US-based company that develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications, announced on Wednesday that it has completed the dosing of participants in the pivotal clinical trial of biosimilar insulin glargine.
The study has not reported any serious adverse events so far.
The company is co-developing the product with its strategic alliance partners within the HEC Group of companies (HEC).
Tim Crew, Lannett chief executive officer, said, 'We achieved the subject enrolment goal to meet our statistical endpoints. Dosing of all subjects has now been completed in the healthy volunteer pharmacokinetics (PK) and pharmacodynamics (PD) study of Lannett/HEC's biosimilar insulin glargine. We continue to expect top-line data and analytics to be available toward the end of this calendar year. We then anticipate filing the Biologics License Application (BLA) for a biosimilar and interchangeable insulin glargine to Sanofi's Lantus Solostar in the Spring of 2023 and potentially launching the product in the first half of 2024.'
ANI Pharmaceuticals Receives FDA Approval, Launches Fluoxetine Oral Solution USP
ANI Pharmaceuticals receives FDA approval for Fluoxetine Oral Solution USP
Prasco Laboratories introduces Authorised Generic of ZIOPTAN in partnership with Thea Pharma
ANI Pharmaceuticals declares FDA approval and commercialisation of Trimethoprim Tablets USP
McKinley, Boothe Named to Maxwell Biosciences Board of Directors
Glenmark Pharmaceuticals USA launches Fingolimod Capsules, 0.5 mg in US
BizCap Secures USD 45m Credit Facility for Nivagen Pharmaceuticals
EpiVax receives USD2m grant to study immunogenicity risk evaluation of host cell proteins
Avacta Launches Phase I Clinical Study of AVA6000 to Advance to the Fourth Cohort
Avacta receives ODD from US Food and Drug Administration for AVA6000 to treat soft tissue sarcoma
Lannett completes participant dosing in biosimilar insulin glargine pivotal clinical trial